LASCCO achieves important milestone for its drug against Severe Pneumococcal Pneumonia

“We are very pleased to receive positive advice from MHRA’s experts on our preclinical and clinical program”, says Frédéric Lajaunias, co-founder and Managing Director of LASCCO. “We will promptly complete the non-clinical program needed to transition to the clinical stage with a view to initiating a first-in-man study, using CAL02 as an adjunctive treatment to standard of care for the treatment of severe pneumococcal pneumonia.”

Severe pneumococcal pneumonia accounts for 20% to 30% of intensive-care units’ patients, with a mortality rate that can exceed 30% despite best currently available therapy. Pre-clinical studies have shown that CAL02 has the potential to combat infections caused by the most frequent bacteria types regardless of their antibiotic resistance profile.

ABOUT CAL02
CAL02 is a broad-spectrum anti-virulence therapeutic agent targeting bacterial toxins for the treatment of severe infections, including those caused by antibiotic-resistant strains. It consists of two lipidic nanoparticles exclusively composed of ubiquitous dietary lipids constituents of the mammalian membranes. CAL02 acts in synergy with the antibiotics and also indirectly affects bacterial survival by depriving bacteria from the tools they use to feed and multiply, and by protecting the immune system, which can then appropriately combat the infection. The product is at preclinical stage.

ABOUT LASCCO
LASCCO SA is a Swiss-based biotechnology company dedicated to the development of discovery-stage biomedical technologies. For more information, please visit the company's website at http://www.lascco.com.